Ticagrelor is the active ingredient in the medication.It is a type of medicine called a platelet aggregation inhibitor.
Prevention of atherothrombotic events (blood clots in the arteries) in patients with acute coronary syndromes (heart attack or unstable angina) who have already received treatment with aspirin.
Prevention of atherothrombotic events in patients with a history of myocardial infarction (heart attack) or stroke.
Brilinta 90mg Tab 180s (Ticagrelor) works by blocking a specific type of receptor on platelets called the P2Y12 receptor. This prevents platelets from sticking together and forming blood clots, which can block blood flow to the heart, brain, or other vital organs.
Store Ticagrelor tablets at room temperature, between 20°C and 25°C (68°F and 77°F). Protect from moisture and light.
The usual starting dose of Ticagrelor is 180 mg once daily for the first day, followed by 90 mg twice daily.
Your doctor may adjust your dose based on your individual needs.
Ticagrelor is taken by mouth with or without food.
It is important to take Ticagrelor exactly as prescribed by your doctor.
The most common side effects of Ticagrelor are bleeding, dizziness, and shortness of breath.
Serious side effects can occur, including bleeding in the brain, stomach, or intestines.
Alcohol can increase the risk of bleeding, so it is important to limit alcohol consumption while taking Ticagrelor.
Ticagrelor can cause dizziness, so it is important to avoid driving or operating machinery until you know how it affects you.
Ticagrelor is not recommended for use during pregnancy. It is not known whether Ticagrelor passes into breast milk, so it is not recommended for use during breastfeeding.
Ticagrelor is not approved for use in children.
Ticagrelor is mainly eliminated by the liver, so it is not recommended for use in patients with severe liver disease.
Ticagrelor is mainly eliminated by the liver, so it is not recommended for use in patients with severe liver disease.
https://www.medicines.org.uk/emc/files/pil.1000.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020660s000lbl.pdf
https://www.mayoclinic.org/diseases-conditions/heart-attack/diagnosis-treatment/drc-20353126
